id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-3114	Di Brizzi, Eugenia Veronica; Buononato, Dario; Benvenuto, Pierfrancesco; Argenziano, Giuseppe; De Pasquale, Rocco ; Fiorella, Carmen Silvia; Gioffrè, Claudia; Musumeci, Maria Letizia; Palazzo, Giovanni; Zichichi, Leonardo; Balato, Anna	Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis	2023	6	.pdf	application/pdf	3672	237	57	E-mail: eugeniaveronica.dibrizzi@gmail.com Introduction: Tildrakizumab is a humanized IgG1κ monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved in 2018 for the treatment of patients with moderate-to-severe chronic plaque psoriasis. Tildrakizumab is a humanized IgG1κ monoclonal an- tibody targeting the p19 subunit of interleukin (IL)-23, approved in 2018 for the treatment of patients with moderate-to-severe chronic plaque psoriasis [2].	cache/dpc-3114.pdf	txt/dpc-3114.txt